FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome

FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome

Estrogen receptor‐alpha (ERα)‐positive breast cancer is often treated with antihormonal regimens. However, resistance to treatment is common, leading to metastatic disease. ERα activity requires the functional involvement of pioneer factors FOXA1 and GATA3, which enable ERα–chromatin binding and are...

Full description

Bibliographic Details
Main Authors: Willemijne Schrijver, Karianne Schuurman, Annelot vanRossum, Marjolein Droog, Carmen Jeronimo, Sofia Salta, Rui Henrique, Jelle Wesseling, Cathy Moelans, Sabine C. Linn, Michel van denHeuvel, Paul vanDiest, Wilbert Zwart
Format: Article
Language:English
Published: Wiley 2018-11-01
Series:Molecular Oncology
Subjects:
acquired endocrine resistance
breast cancer metastasis
FOXA1
GATA3
pleural effusions
Online Access:https://doi.org/10.1002/1878-0261.12353

Internet

https://doi.org/10.1002/1878-0261.12353

Similar Items